^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

simridarlimab (IBI-322)

i
Other names: IBI-322, IBI322, IBI 322
Associations
Company:
Innovent Biologics
Drug class:
PD-L1 inhibitor, CD47 inhibitor
Related drugs:
Associations
8d
A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy (clinicaltrials.gov)
P1, N=70, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Completed | N=230 --> 70
Trial completion • Enrollment change
|
simridarlimab (IBI-322)
1year
Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
P1a/1b, N=94, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | N=218 --> 94 | Trial completion date: Dec 2023 --> Aug 2023
Trial completion • Enrollment change • Trial completion date • Metastases
|
simridarlimab (IBI-322)
1year
A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers (clinicaltrials.gov)
P1a, N=22, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Completed | N=51 --> 22 | Trial completion date: Jul 2023 --> Feb 2023
Trial completion • Enrollment change • Trial completion date • Metastases
|
simridarlimab (IBI-322)
1year
A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor (clinicaltrials.gov)
P1a/1b, N=1, Terminated, Innovent Biologics (Suzhou) Co. Ltd. | N=124 --> 1 | Trial completion date: May 2024 --> Aug 2023 | Not yet recruiting --> Terminated; Due to the company's development strategy adjustment]
Enrollment change • Trial completion date • Trial termination
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
simridarlimab (IBI-322)
over1year
CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY (EHA 2023)
Despite the excellent efficacy of PD-1 or PD-L1 inhibitors and brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (cHL), some patients (pts) still have disease progression. IBI322 monotherapy showed a promising anti-tumor effectivity with a manageable safety profile in anti-PD-1 or PD-L1 treatment-resistant classical Hodgkin Lymphoma patients. Clinical trial information: NCT04795128 Hodgkin's lymphoma, Resistance, Immune therapy
P1 data
|
SIRPA (Signal Regulatory Protein Alpha)
|
Adcetris (brentuximab vedotin) • simridarlimab (IBI-322)
over1year
Efficacy and Biomarker Explanation of IBI-322 +Lenvatinib Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov)
P2, N=80, Not yet recruiting, Hunan Province Tumor Hospital | Initiation date: Jul 2022 --> Mar 2023 | Trial primary completion date: Apr 2023 --> Dec 2023
Trial initiation date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase)
|
ALK rearrangement
|
Alecensa (alectinib) • Lenvima (lenvatinib) • simridarlimab (IBI-322)
over2years
New P2 trial
|
ALK (Anaplastic lymphoma kinase)
|
ALK rearrangement
|
Alecensa (alectinib) • Lenvima (lenvatinib) • simridarlimab (IBI-322)